Glaukos Corp Stock Price, News & Analysis

Glaukos reported strong Q1 2025 financial results with record net sales of $106.7 million, marking a 25% year-over-year increase. The company's Glaucoma segment achieved record sales of $88.1 million, up 31% from the previous year, with U.S. Glaucoma sales reaching $59.1 million, a 41% increase.

Key financial metrics include:

• Gross margin of 77% (82% non-GAAP)
• Operating loss reduced to $20.7 million from $39.1 million year-over-year
• Net loss improved to $18.1 million ($0.32 per share) from $40.8 million ($0.82 per share)

The company maintains a strong financial position with $303.4 million in cash and investments, carrying no debt. Glaukos reaffirmed its 2025 net sales guidance of $475-485 million, demonstrating confidence in continued growth. The company's focus remains on developing novel, dropless platform technologies for chronic eye diseases.

Glaukos (NYSE: GKOS) has announced its participation in the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 25-28 in Los Angeles. The company will showcase its technologies at booth #2227 and sponsor an educational symposium on 'Empowering Interventional Glaucoma Care.'

The scientific program features several key presentations including:

• 10-year glaucoma control outcomes with trabecular micro-bypass
• 12-month results of third-generation trabecular micro-bypass stent
• 36-month outcomes of travoprost intracameral implant
• Studies on corneal collagen cross-linking for keratoconus

Notable speakers include Dr. Fritz Hengerer, Dr. Zachary Vest, Dr. Inder Singh, and Dr. Vance Thompson, presenting research on glaucoma control, medication reduction, and corneal health treatments.

Glaukos (NYSE: GKOS) has released its sixth annual Sustainability Report for 2024, showcasing significant progress in corporate sustainability initiatives. The ophthalmic pharmaceutical and medical technology company reported several key achievements:

• Donated approximately $7 million in products globally, reaching a total of over $17 million in donations to date
• Conducted 45 philanthropic volunteer events with 25 nonprofit organizations, accumulating over 700 volunteer hours
• Expanded patient services program to nearly 5,000 keratoconus patients, totaling 8,000 patients since 2023
• Implemented a two-site distribution model reducing 20 million air miles and 4,000 tons of greenhouse emissions
• Launched the iDose Your Dose initiative, matching each iDose® TR unit sold with a donation to charitable requests

The company also announced plans for a new research facility in Huntsville, Alabama, and introduced enhanced employee benefits including mental health support and student loan repayment programs.

Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for glaucoma, corneal disorders and retinal diseases, has scheduled its first quarter 2025 financial results release for Wednesday, April 30, 2025, after market close.

The company will host a conference call and simultaneous webcast to discuss the results at 1:30 p.m. PT (4:30 p.m. ET) on the same day. Investors can access the webcast through the company's investor relations website, while those wishing to participate in the conference call can dial 800-715-9871 (U.S.) or 646-307-1963 (International) using Conference ID 5255602.

RadiusXR, Topcon Healthcare, and Glaukos (NYSE: GKOS) have announced a strategic collaboration and the launch of Inspire®, a next-generation wearable vision testing platform.

The partnership combines RadiusXR's innovative visual field technology, Topcon's robotic diagnostics expertise, and Glaukos' focus on democratizing ophthalmic disease diagnosis. Inspire is the first commercial wearable vision diagnostic system that integrates visual field testing with patient education and data-driven intelligence.

Under the agreement, Topcon Healthcare will become the exclusive global distributor of the Inspire platform. The six-ounce device is designed for future expansion beyond traditional diagnostics to support testing for other chronic and systemic conditions. The collaboration aims to expand patient access and enable doctors to provide visual field exams to all glaucoma patients requiring testing.

Glaukos (NYSE: GKOS) announced FDA acceptance of its New Drug Application (NDA) for Epioxa™, a next-generation corneal cross-linking therapy for keratoconus treatment. The FDA set a PDUFA date of October 20, 2025, reflecting a standard 10-month review period.

Epioxa is designed as the first FDA-approved, non-invasive corneal cross-linking therapy that doesn't require corneal epithelium removal. The therapy aims to reduce procedure times, improve patient comfort, and shorten recovery time. The NDA submission includes data from two successful Phase 3 pivotal trials showing favorable efficacy, tolerability, and safety profiles.

Keratoconus, typically diagnosed in teenage years, affects approximately 90% of cases bilaterally, with up to 20% of patients requiring corneal transplant. Unlike conventional treatments that only address symptoms, Epioxa uses a proprietary drug formulation with UV-A irradiation and supplemental oxygen to strengthen corneal tissue and halt disease progression.

Glaukos (NYSE: GKOS) reported strong financial results for Q4 and full year 2024. The company achieved record Q4 net sales of $105.5 million, up 28% year-over-year, with glaucoma sales reaching $84.1 million, a 39% increase. Full-year 2024 net sales grew 22% to $383.5 million.

Q4 gross margin was 73% (82% non-GAAP), while operating loss improved to $28.7 million from $38.6 million in Q4 2023. The company reported a Q4 net loss of $33.6 million ($0.60 per share). For the full year 2024, net loss was $146.4 million ($2.77 per share).

Looking ahead, Glaukos provided 2025 net sales guidance of $475-485 million. The company maintains a strong financial position with approximately $324 million in cash and investments, with no debt.

Glaukos (NYSE: GKOS), a company specializing in ophthalmic pharmaceutical and medical technology for treating glaucoma, corneal disorders, and retinal diseases, has announced it will release its fourth quarter and full year 2024 financial results after market close on February 20, 2025.

The company has scheduled a conference call and simultaneous webcast for 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the webcast through the company's investor relations website, while those wishing to participate in the conference call can dial 888-210-2212 (U.S.) or 646-960-0390 (International) using Conference ID 7935742.

Glaukos (NYSE: GKOS) announced positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform. In a 36-month follow-up analysis of Phase 3 trials, iDose TR demonstrated sustained IOP reductions with approximately 70% of subjects remaining well-controlled, compared to 58% of timolol control subjects.

The company has initiated a Phase 2b/3 clinical program for iDose TREX, its next-generation therapy with nearly twice the drug capacity. A 6-month Phase 4 study showed iDose TR combined with cataract surgery achieved a mean IOP reduction of 11.3 mmHg (44%) in open-angle glaucoma patients.

The iDose platform is designed to address patient non-adherence and side effects associated with topical medications by providing 24/7, long-duration efficacy with minimal side effects.